The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback